Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01909453
Title	Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
Acronym	COLUMBUS
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Pfizer
Indications	melanoma
Therapies	Vemurafenib Encorafenib Binimetinib + Encorafenib
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| AUS \| ARG